Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17252487 | COSMETIC COMPOSITION COMPRISING ANIONIC, NON-IONIC AND AMPHOTERIC SURFACTANTS, AT LEAST TWO ORGANOSILANES AND ASSOCIATIVE CATIONIC POLYMERS, COSMETIC TREATMENT PROCESS AND USE | December 2020 | April 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17120965 | POLYGALA EXTRACT FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER | December 2020 | October 2023 | Allow | 34 | 2 | 0 | No | No |
| 17116983 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE-SULFAMIDE | December 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 17114767 | HAIR STRENGTHENING COMPOSITION | December 2020 | September 2023 | Allow | 33 | 2 | 1 | No | No |
| 17104566 | Sustained Release Formulations Using Non-Aqueous Emulsions | November 2020 | March 2023 | Allow | 28 | 2 | 1 | No | No |
| 17055768 | CONJUGATES COMPRISING A TEMPERATURE-RESPONSIVE POLYMER AND A LIGAND CAPABLE OF BINDING ERGOSTEROL | November 2020 | July 2024 | Allow | 44 | 4 | 1 | Yes | No |
| 17086862 | DRUG DELIVERY SYSTEMS COMPRISING SOLID SOLUTIONS OF WEAKLY BASIC DRUGS | November 2020 | July 2024 | Allow | 45 | 3 | 1 | No | No |
| 17072707 | BULK POLYETHYLENE GLYCOL COMPOSITIONS | October 2020 | June 2023 | Allow | 32 | 2 | 1 | No | No |
| 17047542 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF PREGNENOLONE | October 2020 | July 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17045317 | PROTEIN FUNCTIONALIZED HYALURONIC ACID COATED CHITOSAN NANOPARTICLE AND METHOD OF PREPARATION | October 2020 | November 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17045469 | REFILLABLE DRUG DELIVERY BY AFFINITY HOMING | October 2020 | July 2023 | Allow | 33 | 2 | 1 | No | No |
| 17063327 | Nutritional Compositions For The Management of Hyponatremia | October 2020 | February 2022 | Allow | 16 | 1 | 0 | No | No |
| 17043000 | PROCESS FOR CURL-RELAXING AND/OR STRAIGHTENING KERATIN FIBRES, USING A THIOL-BASED REDUCING AGENT AND A DICARBOXYLIC ACID DERIVATIVE, AND STRAIGHTENING KIT | September 2020 | July 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 17029147 | Cosmetic Adhesive Compositions | September 2020 | July 2022 | Allow | 22 | 1 | 0 | No | No |
| 17006262 | Method for the preparation of a 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione system in polysorbates for the formation of micelles in an aqueous medium aimed at the properties of the bioavailability of curcuminoids | August 2020 | September 2024 | Allow | 49 | 5 | 1 | No | No |
| 16976270 | Pharmaceutical Composition with Excellent Storage Stability | August 2020 | May 2025 | Allow | 57 | 2 | 0 | No | No |
| 16971863 | Adhesive Composition | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16996183 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | August 2020 | February 2022 | Allow | 18 | 1 | 0 | No | No |
| 16966793 | ANTIBACTERIAL AND SPERMICIDAL LUBRICANT | July 2020 | September 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16966453 | OCULAR INSERTS COMPRISING A COVALENTLY LINKED STEROID DIMER | July 2020 | November 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16919728 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | July 2020 | September 2021 | Abandon | 15 | 1 | 1 | No | No |
| 16911655 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | June 2020 | April 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16908940 | POROUS PARTICLE AND METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION | June 2020 | January 2023 | Allow | 30 | 3 | 1 | No | No |
| 16904246 | ARIPIPRAZOLE PRODRUG COMPOSITION | June 2020 | September 2021 | Allow | 14 | 2 | 0 | No | No |
| 16899255 | CLOSED CELL FOAMS INCLUDING POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | June 2020 | November 2021 | Allow | 17 | 2 | 0 | No | No |
| 16769501 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | June 2020 | April 2024 | Abandon | 46 | 2 | 1 | No | No |
| 16765883 | Oral Pharmaceutical Composition of an NK-1 Antagonist | May 2020 | April 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16856893 | METHODS AND COMPOSITIONS INHIBITING ENVELOPED VIRUSES USING HIGH MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED ALKALI SWELLABLE EMULSION POLYMERS | April 2020 | January 2024 | Allow | 44 | 3 | 1 | No | No |
| 16755866 | NANOVECTORS AND USES | April 2020 | August 2023 | Allow | 40 | 2 | 1 | No | No |
| 16842855 | METHOD FOR IMPROVING PHARMACOKINETICS | April 2020 | December 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16835940 | PROCESS FOR PRODUCING MICROEMULSION SYSTEM OF NANO ESSENTIAL OIL | March 2020 | January 2023 | Allow | 34 | 2 | 1 | No | No |
| 16650948 | NIRAPARIB FORMULATIONS | March 2020 | February 2023 | Allow | 35 | 3 | 1 | No | No |
| 16816027 | MEAT TREATMENT | March 2020 | November 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16814489 | PHOSPHINOGOLD(I) COMPLEXES AND METHODS OF TREATING CANCER | March 2020 | June 2021 | Allow | 16 | 0 | 1 | No | No |
| 16641559 | TRIPLET-TRIPLET ANNIHILATION UPCONVERSION SYSTEM, AND COMPOSITIONS AND METHODS THEREOF FOR DRUG DELIVERY | February 2020 | April 2021 | Allow | 13 | 1 | 1 | No | No |
| 16779901 | Low-Dose Doxepin Formulations And Methods Of Making And Using The Same | February 2020 | December 2020 | Allow | 11 | 1 | 0 | No | No |
| 16778101 | LONG CHAIN GLYCOLIPIDS USEFUL TO AVOID PERISHING OR MICROBIAL CONTAMINATION OF MATERIALS | January 2020 | July 2022 | Allow | 30 | 3 | 1 | Yes | No |
| 16634486 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | January 2020 | July 2023 | Allow | 41 | 2 | 1 | No | No |
| 16632759 | NANOPARTICLE COMPOSITIONS | January 2020 | January 2023 | Allow | 36 | 4 | 1 | Yes | No |
| 16631339 | MEDICAL DEVICE AND METHOD FOR MANUFACTURING THE SAME | January 2020 | October 2021 | Allow | 21 | 2 | 1 | Yes | No |
| 16740064 | Slippery Anti-Fouling Surfaces Fabricated from Reactive Polymer Multilayers | January 2020 | February 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16726375 | BIOADHESIVE HYDROGELS | December 2019 | August 2021 | Allow | 20 | 2 | 0 | No | No |
| 16725466 | ORTHOPEDIC IMPLANT HAVING A CRYSTALLINE CALCIUM PHOSPHATE COATING AND METHODS FOR MAKING THE SAME | December 2019 | March 2021 | Allow | 15 | 1 | 1 | No | No |
| 16621893 | TINOSTAMUSTINE FOR USE IN TREATING OVARIAN CANCER | December 2019 | October 2023 | Allow | 46 | 4 | 0 | Yes | No |
| 16618759 | GASTRIC RESIDENCE SYSTEMS WITH RELEASE RATE-MODULATING FILMS | December 2019 | November 2023 | Allow | 47 | 3 | 1 | Yes | No |
| 16676911 | NOVEL SALTS OF 3-[(DIMETHYLAMINO)METHYL]-N-{2-[4-(HYDROXYCARBAMOYL) PHENOXY]ETHYLI-1-BENZOFURAN-2-CARBOXAMIDE, RELATED CRYSTALLINE FORMS, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | November 2019 | September 2020 | Allow | 10 | 0 | 0 | No | No |
| 16608989 | COSMETIC COMPOSITION | October 2019 | April 2022 | Abandon | 29 | 3 | 0 | No | No |
| 16656169 | ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME | October 2019 | December 2020 | Allow | 14 | 3 | 0 | No | No |
| 16656157 | ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME | October 2019 | September 2021 | Allow | 23 | 2 | 0 | No | No |
| 16656178 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | October 2019 | November 2020 | Allow | 13 | 2 | 0 | No | No |
| 16656268 | DRUG RELEASING COATINGS FOR BALLOON CATHETERS | October 2019 | September 2020 | Allow | 11 | 1 | 0 | No | No |
| 16656289 | DRUG RELEASING COATINGS FOR BALLOON CATHETERS | October 2019 | September 2020 | Allow | 11 | 1 | 0 | No | No |
| 16598299 | MANUFACTURING METHOD FOR GRANULE | October 2019 | July 2023 | Allow | 45 | 4 | 1 | Yes | No |
| 16603399 | COMPOSITION FOR FORMING COATING | October 2019 | October 2022 | Allow | 37 | 4 | 1 | Yes | No |
| 16498299 | AGENTS FOR INCREASING MEIBOMIAN GLAND LIPID SECRETION | September 2019 | June 2022 | Allow | 33 | 3 | 1 | No | No |
| 16570944 | LIPOPHILLICALLY DISPERSED PHENOLIC POLYMER PARTICLES | September 2019 | June 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16492238 | METHOD AND MATERIAL FOR DIFFERENTIATED SEQUESTRATION OF SUBSTANCES OF DIFFERENT SUBSTANCE GROUPS WITH THE AID OF HYDROGELS CONTAINING SULPHATED OR SULPHONATED COMPONENTS | September 2019 | October 2024 | Abandon | 60 | 4 | 1 | Yes | No |
| 16547348 | ROS-DEGRADEABLE HYDROGELS | August 2019 | October 2021 | Abandon | 26 | 2 | 1 | No | No |
| 16486449 | ORALLY ADMINISTRABLE MODIFIED-RELEASED PHARMACEUTICAL DOSAGE FORM | August 2019 | March 2024 | Abandon | 55 | 5 | 1 | Yes | No |
| 16480266 | COMPOSITION, DEVICE AND METHOD FOR CONFORMATIONAL INTRA-TISSUE BETA BRACHYTHERAPY | July 2019 | February 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16476559 | SYNERGISTS FOR IMPROVED PESTICIDES | July 2019 | June 2022 | Abandon | 36 | 3 | 1 | No | No |
| 16472449 | STICK-TYPE SOLID BASE MATERIAL FOR EXTERNAL APPLICATION TO SKIN | June 2019 | April 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16442049 | NIRAPARIB SUSTAINED AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND USE THEREOF | June 2019 | September 2021 | Abandon | 27 | 2 | 1 | No | No |
| 16436590 | SUBCUTANEOUS DELIVERY OF POLY(OXAZOLINE) POLYMER CONJUGATES | June 2019 | September 2021 | Allow | 27 | 1 | 1 | No | No |
| 16428534 | HYDROGEL PRECURSORS HAVING NANOPARTICLES | May 2019 | January 2021 | Allow | 19 | 1 | 1 | Yes | No |
| 16416818 | ARIPIPRAZOLE PRODRUG COMPOSITION | May 2019 | February 2020 | Allow | 9 | 2 | 0 | Yes | No |
| 16347929 | Foaming Resin Composition, Preparation Method Therefor, and Foam Using Same | May 2019 | February 2022 | Allow | 34 | 2 | 1 | No | No |
| 16339299 | S-NITROSOTHIOL-MEDIATED HYPERBRANCHED POLYESTERS | April 2019 | July 2021 | Allow | 28 | 2 | 1 | No | No |
| 16291499 | SOLID COMPOSITIONS OF ACTIVES, PROCESSES FOR PREPARING SAME AND USES OF SUCH SOLID COMPOSITIONS | March 2019 | December 2022 | Abandon | 46 | 5 | 1 | Yes | No |
| 16321839 | POLYAMIDOAMINES WITH ANTIMICROBIAL ACTIVITY | January 2019 | April 2020 | Allow | 14 | 2 | 1 | No | No |
| 16321859 | POLYMER NANOPARTICLE, POLYMER COMPOSITION, METHOD OF MAKING A POLYMER NANOPARTICLE, METHOD FOR TREATMENT OF BACTERIAL BIOFILMS, AND METHOD FOR DETECTION OF BACTERIAL BIOFILMS | January 2019 | January 2022 | Allow | 35 | 3 | 1 | No | No |
| 16245983 | Stabilized Calcium Phosphate | January 2019 | May 2021 | Allow | 28 | 2 | 1 | No | No |
| 16225433 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE | December 2018 | July 2021 | Allow | 31 | 1 | 1 | No | No |
| 16223552 | COATINGS CONTAINING MULTIPLE DRUGS | December 2018 | January 2021 | Allow | 25 | 3 | 0 | No | No |
| 16306979 | COMPOSITE SOLS | December 2018 | March 2023 | Allow | 51 | 4 | 1 | No | No |
| 16183155 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | November 2018 | November 2022 | Abandon | 49 | 4 | 0 | No | No |
| 16091716 | ISOFLAVONOID COMPOSITION WITH IMPROVED PHARMACOKINETICS | October 2018 | October 2022 | Allow | 48 | 4 | 1 | Yes | No |
| 16088759 | GEL COMPOSITION, COSMETIC, AND METHOD FOR PRODUCING GEL COMPOSITION | September 2018 | February 2021 | Allow | 28 | 2 | 0 | No | No |
| 16131639 | Use of a Polyanionic Composition | September 2018 | May 2021 | Allow | 32 | 2 | 1 | No | No |
| 16125358 | CHOLESTYRAMINE GRANULES, ORAL CHOLESTYRAMINE FORMULATIONS AND USE THEREOF | September 2018 | September 2020 | Allow | 24 | 3 | 0 | No | No |
| 16121023 | POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | September 2018 | April 2022 | Allow | 44 | 6 | 1 | Yes | No |
| 16117303 | POLYMERIC NANOPARTICLES AND A PROCESS OF PREPARATION THEREOF | August 2018 | August 2021 | Allow | 36 | 2 | 1 | Yes | No |
| 16079589 | PHARMACEUTICAL COMPOSITION COMPRISING PYRROLO-FUSED SIX-MEMBERED HETEROCYCLIC COMPOUND | August 2018 | January 2021 | Allow | 28 | 3 | 1 | No | No |
| 16077355 | TRANSDERMAL UV-CURABLE HYDROGEL RESIN, HYDROGEL CURING THE SAME AND CATAPLASM CONTAINING THE SAME | August 2018 | May 2022 | Allow | 45 | 2 | 1 | No | No |
| 16058887 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | August 2018 | December 2020 | Abandon | 28 | 1 | 1 | No | No |
| 16075994 | POROUS MATERIAL | August 2018 | November 2021 | Allow | 39 | 2 | 1 | No | No |
| 16054019 | CONTROLLED RELEASE COMPOSITION AND METHOD | August 2018 | June 2022 | Abandon | 46 | 3 | 0 | No | No |
| 16048432 | COMPOSITION AND METHOD FOR IMPROVING AND PROTECTING KERATINS | July 2018 | April 2021 | Allow | 32 | 2 | 0 | Yes | No |
| 16033177 | METHOD FOR IMPROVING PHARMACOKINETICS | July 2018 | June 2020 | Abandon | 23 | 1 | 0 | No | No |
| 16024729 | ARIPIPRAZOLE PRODRUG COMPOSITION | June 2018 | July 2020 | Allow | 25 | 1 | 0 | Yes | No |
| 16023940 | METHOD FOR TREATING AN AUTOIMMUNE NEUROLOGICAL DISEASE AND/OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | June 2018 | March 2022 | Allow | 44 | 3 | 1 | No | No |
| 16064079 | EMULSION CONCENTRATES OF LIPOPHILIC COMPOUNDS | June 2018 | February 2022 | Allow | 44 | 3 | 1 | No | No |
| 16064129 | USE OF DIHYDROISOQUINOLINIUM DOUBLE DERIVATIVES FOR TREATING KERATIN MATERIALS, COMPOSITIONS AND IMPLEMENTATION PROCESSES | June 2018 | April 2022 | Allow | 46 | 3 | 1 | No | No |
| 16064256 | USE OF DIHYDROISOQUINOLINIUM SALTS FOR TREATING KERATIN MATERIALS, COMPOSITIONS AND IMPLEMENTATION PROCESSES | June 2018 | April 2022 | Allow | 46 | 3 | 1 | No | No |
| 15781246 | LIGHT-ACTIVATED PREPARATION OF HYDROGELS | June 2018 | January 2021 | Allow | 31 | 2 | 1 | Yes | No |
| 15988210 | ORAL CHOLESTYRAMINE FORMULATION AND USE THEREOF | May 2018 | August 2020 | Allow | 27 | 4 | 0 | Yes | No |
| 15988202 | ORAL CHOLESTYRAMINE FORMULATION AND USE THEREOF | May 2018 | August 2020 | Allow | 27 | 3 | 0 | No | No |
| 15979955 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | May 2018 | June 2021 | Allow | 37 | 2 | 1 | No | No |
| 15980279 | Pharmaceutical Compositions of Fumaric Acid Esters | May 2018 | June 2021 | Allow | 37 | 3 | 1 | No | No |
| 15772759 | Functionalized Mesoporous Silica via an Aminosilane Surfactant Ion Exchange Reaction: Controlled Scaffold Design and Nitric Oxide Release | May 2018 | April 2022 | Allow | 47 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHEELER, THURMAN MICHAEL.
With a 31.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WHEELER, THURMAN MICHAEL works in Art Unit 1619 and has examined 596 patent applications in our dataset. With an allowance rate of 42.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner WHEELER, THURMAN MICHAEL's allowance rate of 42.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WHEELER, THURMAN MICHAEL receive 2.94 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WHEELER, THURMAN MICHAEL is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +29.3% benefit to allowance rate for applications examined by WHEELER, THURMAN MICHAEL. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.2% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.0% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 94.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 63.5% of appeals filed. This is in the 43% percentile among all examiners. Of these withdrawals, 54.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 73% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.